ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,021.63
0.57%
US Tech 100
20,367.60
0.51%
다우존스 지수
44,860.31
0.28%
Bitcoin
92,660.51
0.75%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NYSE

  6. Amneal Pharmaceuticals Holding Co (AMRX) 시세

Amneal Pharmaceuticals Holding Co

Amneal Pharmaceuticals Holding Co (AMRX)

Amneal Pharmaceuticals Inc
5.87
0.00
(0.00%)
마감 27 11월 6:00AM
15분 지연
0.00
0.00
(0.00%)
시간외 거래: -
15분 지연

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

주요 통계 및 세부정보

가격
5.87
매수가
-
매도가
-
거래량
-
0.00 일간 변동폭 0.00
0.00 52주 범위 0.00
market_cap
1.817B
전일 종가
5.87
개장가
-
최근 거래 시간
마지막 거래 시간
재정 규모
-
VWAP
-
평균 볼륨(3m)
-
발행 주식
309,542,608
배당수익률
-
주가수익률
-21.64
주당순이익(EPS)
-0.27
매출
2.41B
순이익
-83.99M

Amneal Pharmaceuticals Holding Co 정보

Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products, Specialty products, and AvKARE. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inha... Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products, Specialty products, and AvKARE. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and the Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
www.amneal.com
본부
Wilmington, Delaware, USA
설립됨
-

AMRX 최신 뉴스

추가 뉴스

Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration

Represents Amneal’s fourth 505(b)(2) injectable approval in 2024 Ready-to-use oncology treatment used for multiple myeloma and mantle cell lymphoma Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX...

06 9월 2024
Business Wire

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Propofol is an essential surgical anesthetic in hospitals that is in chronic shortage Complex emulsion injectable expands Amneal’s injectables portfolio Amneal Pharmaceuticals, Inc. (Nasdaq:...

21 8월 2024
Business Wire

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Propofol is an essential surgical anesthetic in hospitals that is in chronic shortage Complex emulsion injectable expands Amneal’s injectables portfolio Amneal Pharmaceuticals, Inc. (Nasdaq:...

20 8월 2024
Business Wire

Form 144 - Report of proposed sale of securities

15 8월 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

15 8월 2024
Edgar (US Regulatory)

Amneal Reports Second Quarter 2024 Financial Results

‒ Q2 2024 Net Revenue of $702 million; GAAP Net Income of $6 million; Diluted Income per Share of $0.02 ‒ ‒ Adjusted EBITDA of $162 million; Adjusted Diluted EPS of $0.16 ‒ ‒ Raising 2024 Full...

09 8월 2024
Business Wire

Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules

Delivers more “Good On” time with less frequent dosing compared to Immediate Release CD/LD Underscores Amneal’s leadership in Parkinson’s disease and commitment to one million people currently...

08 8월 2024
Business Wire

Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags

First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will launch in third quarter Amneal Pharmaceuticals...

30 7월 2024
Business Wire

Amneal to Report Second Quarter 2024 Results on August 9, 2024

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company...

12 7월 2024
Business Wire

Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant

FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched...

10 7월 2024
Business Wire
기간변동변동 %시가고가저가평균 일일 거래량VWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
QDQudian Inc
US$ 3.02
(31.88%)
3.35M
TSETrinseo Plc
US$ 4.44
(17.15%)
587.76k
DAOYoudao Inc
US$ 6.09
(14.91%)
368.71k
SMRTSmartRent Inc
US$ 1.855
(14.51%)
2.22M
REREATRenew Inc
US$ 3.12
(13.87%)
2.37M
SEMSelect Medical Holdings Corporation
US$ 21.33
(-44.88%)
2.43M
KSSKohls Corporation
US$ 15.215
(-17.04%)
58.72M
TBBBBBB Foods Inc
US$ 29.79
(-12.79%)
2.02M
DBIDesigner Brands Inc
US$ 4.82
(-12.68%)
2.47M
FOAFinance of America Companies Inc
US$ 17.60
(-10.93%)
135.95k
NIONIO Inc
US$ 4.32
(-7.49%)
71.25M
KSSKohls Corporation
US$ 15.215
(-17.04%)
58.87M
FFord Motor Company
US$ 11.09
(-2.72%)
47.46M
ACHRArcher Aviation Inc
US$ 7.225
(-3.41%)
39.61M
NUNu Holdings Ltd
US$ 13.9325
(-2.09%)
34.49M

AMRX Discussion

게시물 보기
Monksdream Monksdream 7 월 전
AMRX under $10
👍️0
Monksdream Monksdream 8 월 전
AMRX under $10
👍️0
Luckypennyman Luckypennyman 2 년 전
Amarin Announces New REDUCE-IT® Data. March 5, 2023.

DUBLIN, Ireland and BRIDGEWATER, N.J., March 05, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced a new analysis from the VASCEPA/VAZKEPA (icosapent ethyl) cardiovascular outcomes REDUCE-IT study showing the effectiveness of VASCEPA®/VAZKEPA® in patients with recent acute coronary syndrome (<12 months before randomization). This post-hoc analysis showed that icosapent ethyl (IPE) substantially and significantly reduced the risk of first and total ischemic events by 37% and 36% respectively in patients with recent acute coronary syndrome (ACS) without increasing bleeding, supporting early initiation of IPE after ACS. The data were presented at the American College of Cardiology’s 72nd Annual Scientific Session together with the World Heart Federation’s World Congress of Cardiology in New Orleans, LA.

https://healthstockshub.com/news/nasdaq/amrn/amarin-announces-new-reduce-it-data-at-acc-23-wcc-showing-benefit-of-vascepa-vazkepa-icosapent-ethyl-in-high-risk-patients-with-a-recent-acute-coronary-syndrome-event
👍️0
Jake L Jake L 3 년 전
AMRX - Update

👍️0
TrendTrade2016 TrendTrade2016 4 년 전
monster bio beast ready to beast in beast land!!
👍️0
ClayTrader ClayTrader 4 년 전
* * $AMRX Video Chart 03-08-2021 * *

Link to Video - click here to watch the technical chart video

👍️0
ListenToMe ListenToMe 4 년 전
AMRX is a good long term hold.
👍️0
ListenToMe ListenToMe 4 년 전
I was hoping AMRX would have better news
👍️0
ListenToMe ListenToMe 4 년 전
Any opinions on AMRX for 2021?
👍️0
ListenToMe ListenToMe 4 년 전
AMRX... the time will come.!
👍️0
ListenToMe ListenToMe 4 년 전
Looks like amrx is going into the 3's
👍️0
ListenToMe ListenToMe 4 년 전
I agree AMRX needs a good catalyst to bring some well deserved attention to this company!

AMRX has huge potential!!
👍️0
Elpapibh Elpapibh 4 년 전
It’s a fantastic play, it’s just they’re in the background and no demand for shares can keep this where it’s at
👍️0
ListenToMe ListenToMe 4 년 전
I'm still thinking AMRX will be a great Sleeper play!!
👍️0
ListenToMe ListenToMe 4 년 전
AMRX is getting a little bounce today. nice
👍️0
Elpapibh Elpapibh 4 년 전
No demand, yet
👍️0
ListenToMe ListenToMe 4 년 전
I'm really surprised this thing isn't 4X Higher.

AMRX
👍️0
Elpapibh Elpapibh 4 년 전
Close to 2 bil market cap no reason for such a dip. Let’s see how the re-recovery looks.
👍️0
Elpapibh Elpapibh 4 년 전
Let’s see what these earnings dooo
👍️0
Elpapibh Elpapibh 4 년 전
Another snack of a close.!! Who’s riding this wave with me???
👍️0
Elpapibh Elpapibh 4 년 전
Fantastic close...
👍️0
Elpapibh Elpapibh 4 년 전
Did I jump on the train too late? I think not. Why isn’t this company forum more popping?
👍️0
ListenToMe ListenToMe 4 년 전
AMRX could be a doubler by end of year!
👍️0
ListenToMe ListenToMe 4 년 전
Amneal is a solid company and will pay off big.
👍️0
Bngo Bngo 4 년 전
With President Trump trying to bring API manufacturing back to The USA to help us rely less on China and India, hopefully all US drug manufacturers can all benefit from this move including Amneal.

Here is a good reason why Amneal is a great candidate for long term success.

https://investors.amneal.com/news/press-releases/press-release-details/2019/Amneal-to-Acquire-Majority-Interest-in-AvKARE-Enhancing-Access-to-Growing-Federal-Healthcare-Market/default.aspx
👍️0
dangerx dangerx 4 년 전
Nice week AMRX ??
👍️0
dangerx dangerx 4 년 전
Shorts and scares. Plus the whole generic pharmaceutical market has been in the crapper for years. Amneal has done great things during that time like launching high value generics and acquiring valuable manufacturers and distributors. It’s only a matter of time before their NDAs and bioequivalents start being major profit centers. Glad you’re on board with this little pharmaceutical company that could (and has!)
👍️0
ListenToMe ListenToMe 4 년 전
I agree AMRX is a big Winner!!
👍️0
Bngo Bngo 4 년 전
This should be a good reason why Amneal is a great candidate for long term success.


https://investors.amneal.com/news/press-releases/press-release-details/2019/Amneal-to-Acquire-Majority-Interest-in-AvKARE-Enhancing-Access-to-Growing-Federal-Healthcare-Market/default.aspx
👍️0
Bngo Bngo 4 년 전
I like the company with its promising government contract, but why are we still so far away from $182?
👍️0
ListenToMe ListenToMe 4 년 전
AMRX is my fav. Pharma play.
👍️0
ListenToMe ListenToMe 4 년 전
AMRX ... buy the dip.
Very solid company.
👍️0
ListenToMe ListenToMe 4 년 전
AMRX is a GREAT long-term play.
Many drugs in the pipeline, sales have been consistently increasing and its a US manufacturer.

WIN WIN WIN


AMRX
👍️0
ListenToMe ListenToMe 4 년 전
AMRX has huge potential. Positioned perfectly to capitalize on the rebirth of US drugs!
👍️0
dangerx dangerx 4 년 전
I think institutional investors might come to play too. I’m pretty sure it was over 90% last year and now 69% according to schwab. If that number grows I’ll have 0 worries here.
👍️0
ListenToMe ListenToMe 4 년 전
#FACT...$182 was the price target last year for AMRX. From at least TWO (2) major analysts.


AMRX = Big $$$$

👍️0
ListenToMe ListenToMe 4 년 전
As I was saying... AMRX is quietly laying the groundwork for significant developments!$$$


AMRX = Extremely Strong BUY$$$$....



BOOM
👍️0
ListenToMe ListenToMe 4 년 전
AMRX is just cruising along and laying low right now...BUT the day of recognition is coming!!$$

And it will be one of the Most talked about companies in the world ??!$$$

AMRX
👍️0
ListenToMe ListenToMe 4 년 전
Now you're talking!!
I like the sound of that.

AMRX is Awesome!!!
👍️0
dangerx dangerx 4 년 전
Shorts cover, approval for biosimilar meds, or Kodak’s grant gets cancelled and goes to AMRX instead.

I’d be happy with a short squeeze.
👍️0
ListenToMe ListenToMe 4 년 전
So I'm trying to figure out what would be a great catalyst to make AMRX surge to the next level above $20.00 range.

Hmmmmm
👍️0
ListenToMe ListenToMe 4 년 전
Lots of interest in AMRX.
👍️0
dangerx dangerx 4 년 전
Things haven’t even got going yet... This is just the tap water in the pot when you first turn on the burner.
👍️0
ListenToMe ListenToMe 4 년 전
And.... HERE WE GO!!$$$

amrx
👍️0
ListenToMe ListenToMe 4 년 전
Looking Very Strong!!

AMRX
👍️0
ListenToMe ListenToMe 4 년 전
Can't go wrong with AMRX!!!
👍️0
ListenToMe ListenToMe 4 년 전
Can't go wrong with AMRX!!!
👍️0
ListenToMe ListenToMe 5 년 전
AMRX... $5.00 - $10.00 - $50.00 - $100+ !!!$$$$
👍️0
ListenToMe ListenToMe 5 년 전
$182 was the price target last year for AMRX. From TWO major analysts.
👍️0
ListenToMe ListenToMe 5 년 전
Insiders are loading AMRX.

Value buyers are buying.

AMRX IS the Most undervalued pharma stock .
👍️0

최근 히스토리

NYSE
AMRX
Amneal Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유